

**UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

**OMB APPROVAL**

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>FMR LLC</u>  (Last) (First) (Middle) <u>245 SUMMER STREET</u>  (Street) <u>BOSTON MA 02210</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/20/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Turnstone Biologics Corp. [ TSBX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <p align="center"><u>See Remark 1</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series D Preferred Stock	(1)	(1)	Common Stock	91,663	(1)	I	F-Prime Capital Partners Healthcare Fund V LP
Series C Preferred Stock	(1)	(1)	Common Stock	106,496	(1)	I	F-Prime Capital Partners Healthcare Fund V LP
Series B-2 Preferred Stock	(1)	(1)	Common Stock	150,809	(1)	I	F-Prime Capital Partners Healthcare Fund V LP
Series B-1 Preferred Stock	(1)	(1)	Common Stock	483,684	(1)	I	F-Prime Capital Partners Healthcare Fund V LP
Series B-2 Preferred Stock	(1)	(1)	Common Stock	296,396	(1)	I	Impresa Fund III Limited Partnership
Series B-2 Preferred Stock	(1)	(1)	Common Stock	4,939	(1)	I	F-Prime Capital Partners Healthcare Advisors Fund V LP

**Explanation of Responses:**

1. The Series B-1, B-2, C, and D Preferred Shares are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.

